High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

BACKGROUND: Tuberculosis is the world's leading infectious disease killer. We aimed to identify shorter, safer drug regimens for the treatment of tuberculosis. METHODS: We did a randomised controlled, open-label trial with a multi-arm, multi-stage design. The trial was done in seven sites in So...

Descripción completa

Detalles Bibliográficos
Autores principales: Boeree, Martin J, Heinrich, Norbert, Aarnoutse, Rob, Diacon, Andreas H, Dawson, Rodney, Rehal, Sunita, Kibiki, Gibson S, Churchyard, Gavin, Sanne, Ian, Ntinginya, Nyanda E, Minja, Lilian T, Hunt, Robert D, Charalambous, Salome, Hanekom, Madeleine, Semvua, Hadija H, Mpagama, Stellah G, Manyama, Christina, Mtafya, Bariki, Reither, Klaus, Wallis, Robert S, Venter, Amour, Narunsky, Kim, Mekota, Anka, Henne, Sonja, Colbers, Angela, van Balen, Georgette Plemper, Gillespie, Stephen H, Phillips, Patrick P J, Hoelscher, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159618/
https://www.ncbi.nlm.nih.gov/pubmed/28100438
http://dx.doi.org/10.1016/S1473-3099(16)30274-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159618/
https://www.ncbi.nlm.nih.gov/pubmed/28100438
http://dx.doi.org/10.1016/S1473-3099(16)30274-2

Ejemplares similares